Chardan Capital Brokers Raise Earnings Estimates for Oculis

Oculis Holding AG (NASDAQ:OCS) – Chardan Capital boosted their FY2025 earnings per share estimates for shares of Oculis in a report released on Tuesday, November 11th. Chardan Capital analyst D. Gataulin now anticipates that the company will earn ($2.44) per share for the year, up from their previous estimate of ($2.73). Chardan Capital currently has a “Buy” rating and a $51.00 target price on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. Chardan Capital also issued estimates for Oculis’ FY2026 earnings at ($2.55) EPS.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%.

Several other brokerages have also recently issued reports on OCS. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Bank of America lowered their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday. Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a research report on Sunday, September 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of Oculis in a research report on Tuesday. Finally, HC Wainwright lifted their target price on Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.80.

Oculis Price Performance

OCS opened at $19.29 on Friday. The company has a market capitalization of $1.01 billion, a P/E ratio of -7.65 and a beta of 0.30. Oculis has a 1-year low of $14.00 and a 1-year high of $23.08. The company has a 50-day moving average of $19.15 and a 200-day moving average of $18.62. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.55 and a current ratio of 4.47.

Hedge Funds Weigh In On Oculis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pivotal bioVenture Partners Investment Advisor LLC increased its position in Oculis by 32.4% in the 1st quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock valued at $43,784,000 after acquiring an additional 563,078 shares during the period. SR One Capital Management LP acquired a new position in Oculis during the 1st quarter worth $6,137,000. Aberdeen Group plc grew its stake in shares of Oculis by 24.1% in the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock worth $23,847,000 after purchasing an additional 243,695 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Oculis during the first quarter valued at $2,499,000. Finally, Marshall Wace LLP bought a new stake in shares of Oculis during the second quarter valued at about $393,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.